Literature DB >> 17464914

Evaluation of antimicrobial therapy orders circumventing an antimicrobial stewardship program: investigating the strategy of "stealth dosing".

Lori Ann LaRosa1, Neil O Fishman, Ebbing Lautenbach, Ross J Koppel, Knashawn H Morales, Darren R Linkin.   

Abstract

OBJECTIVE: Prior-approval antimicrobial stewardship programs (ASPs) improve patient outcomes and decrease antimicrobial resistance. These benefits would be limited if physicians circumvented ASP efforts. We evaluated whether prescribers wait until after the prior-approval period to order restricted antimicrobial therapy that is in conflict with guidelines or unnecessary.
DESIGN: A cross-sectional study design and a retrospective cohort study design.
SETTING: A tertiary care, academic medical center with a prior-approval ASP that was active between 8 am and 10 pm.
METHODS: We evaluated whether there was an increase in the proportion of orders for antimicrobial therapy that involve restricted (vs nonrestricted) antimicrobials during the first hour that the ASP is inactive (ie, the first hour that prior approval is not required), compared with the remainder of the day. We also evaluated whether restricted antimicrobial therapy ordered during this first hour is less likely to be continued when the ASP becomes active the next day, compared with that ordered during the preceding hour.
RESULTS: A greater proportion of the antimicrobial therapy orders placed between 10:00 pm and 10:59 pm were for restricted agents, compared with orders placed during other periods (57.0% vs 49.9%; P=.02). Surgical patients for whom antimicrobial therapy orders were placed between 10:00 pm and 10:59 pm were less likely to have that antimicrobial therapy continued, compared with patients whose therapy was ordered between 9:00 pm and 9:59 pm (60.0% vs 98.1%; P<.001). Nonsurgical patients whose therapy orders were placed between 10:00 pm and 10:59 pm were also less likely to have the ordered antimicrobial therapy continued, compared with patients whose therapy was ordered between 9:00 pm and 9:59 pm (70.8% vs 84.2%; P=.01).
CONCLUSION: Physicians avoid having to obtain prior approval for therapy involving restricted antimicrobials by waiting until restrictions are no longer active to place orders. Compared with restricted antimicrobial therapy ordered when the ASP is active, these courses of therapy are less often continued by the ASP, suggesting that they are more likely to be in conflict with guidelines or unnecessary.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17464914      PMCID: PMC3089023          DOI: 10.1086/513535

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  13 in total

1.  Error, stress, and teamwork in medicine and aviation: cross sectional surveys.

Authors:  J B Sexton; E J Thomas; R L Helmreich
Journal:  BMJ       Date:  2000-03-18

2.  Practices to improve antimicrobial use at 47 US hospitals: the status of the 1997 SHEA/IDSA position paper recommendations. Society for Healthcare Epidemiology of America/Infectious Diseases Society of America.

Authors:  R M Lawton; S K Fridkin; R P Gaynes; J E McGowan
Journal:  Infect Control Hosp Epidemiol       Date:  2000-04       Impact factor: 3.254

3.  Impact of a hospital-based antimicrobial management program on clinical and economic outcomes.

Authors:  R Gross; A S Morgan; D E Kinky; M Weiner; G A Gibson; N O Fishman
Journal:  Clin Infect Dis       Date:  2001-07-05       Impact factor: 9.079

Review 4.  Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital.

Authors:  J F John; N O Fishman
Journal:  Clin Infect Dis       Date:  1997-03       Impact factor: 9.079

5.  Formulary control of antimicrobial usage. What price freedom?

Authors:  W C Dunagan; G Medoff
Journal:  Diagn Microbiol Infect Dis       Date:  1993 Mar-Apr       Impact factor: 2.803

Review 6.  Adjustments for center in multicenter studies: an overview.

Authors:  A R Localio; J A Berlin; T R Ten Have; S E Kimmel
Journal:  Ann Intern Med       Date:  2001-07-17       Impact factor: 25.391

7.  Lying to each other: when internal medicine residents use deception with their colleagues.

Authors:  M J Green; N J Farber; P A Ubel; D T Mauger; B M Aboff; J M Sosman; R M Arnold
Journal:  Arch Intern Med       Date:  2000 Aug 14-28

8.  Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes.

Authors:  A C White; R L Atmar; J Wilson; T R Cate; C E Stager; S B Greenberg
Journal:  Clin Infect Dis       Date:  1997-08       Impact factor: 9.079

9.  Role of computerized physician order entry systems in facilitating medication errors.

Authors:  Ross Koppel; Joshua P Metlay; Abigail Cohen; Brian Abaluck; A Russell Localio; Stephen E Kimmel; Brian L Strom
Journal:  JAMA       Date:  2005-03-09       Impact factor: 56.272

10.  A pseudo-outbreak of nosocomial infections associated with the introduction of an antibiotic management programme.

Authors:  D P Calfee; J Brooks; N M Zirk; E T Giannetta; W M Scheld; B M Farr
Journal:  J Hosp Infect       Date:  2003-09       Impact factor: 3.926

View more
  11 in total

1.  Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases.

Authors:  K de With; F Allerberger; S Amann; P Apfalter; H-R Brodt; T Eckmanns; M Fellhauer; H K Geiss; O Janata; R Krause; S Lemmen; E Meyer; H Mittermayer; U Porsche; E Presterl; S Reuter; B Sinha; R Strauß; A Wechsler-Fördös; C Wenisch; W V Kern
Journal:  Infection       Date:  2016-06       Impact factor: 3.553

Review 2.  Interventions to improve antibiotic prescribing practices for hospital inpatients.

Authors:  Peter Davey; Charis A Marwick; Claire L Scott; Esmita Charani; Kirsty McNeil; Erwin Brown; Ian M Gould; Craig R Ramsay; Susan Michie
Journal:  Cochrane Database Syst Rev       Date:  2017-02-09

3.  Clinical diagnoses and antimicrobials predictive of pediatric antimicrobial stewardship recommendations: a program evaluation.

Authors:  Jennifer L Goldman; Brian R Lee; Adam L Hersh; Diana Yu; Leslie M Stach; Angela L Myers; Mary Anne Jackson; James C Day; Russell J McCulloh; Jason G Newland
Journal:  Infect Control Hosp Epidemiol       Date:  2015-03-16       Impact factor: 3.254

4.  Unintended consequences of information technologies in health care--an interactive sociotechnical analysis.

Authors:  Michael I Harrison; Ross Koppel; Shirly Bar-Lev
Journal:  J Am Med Inform Assoc       Date:  2007-06-28       Impact factor: 4.497

5.  Antimicrobial stewardship: attempting to preserve a strategic resource.

Authors:  Trevor Van Schooneveld
Journal:  J Community Hosp Intern Med Perspect       Date:  2011-07-18

Review 6.  Antimicrobial Stewardship Programs: Appropriate Measures and Metrics to Study their Impact.

Authors:  Andrew M Morris
Journal:  Curr Treat Options Infect Dis       Date:  2014

7.  Evaluating carbapenem restriction practices at a private hospital in Manila, Philippines as a strategy for antimicrobial stewardship.

Authors:  Kaitlin F Mitchell; Nasia Safdar; Cybele L Abad
Journal:  Arch Public Health       Date:  2019-07-04

8.  The Association of Antibiotic Stewardship With Fluoroquinolone Prescribing in Michigan Hospitals: A Multi-hospital Cohort Study.

Authors:  Valerie M Vaughn; Tejal Gandhi; Anna Conlon; Vineet Chopra; Anurag N Malani; Scott A Flanders
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

Review 9.  Antimicrobial Stewardship: Fighting Antimicrobial Resistance and Protecting Global Public Health.

Authors:  Md Anwarul Azim Majumder; Sayeeda Rahman; Damian Cohall; Ambadasu Bharatha; Keerti Singh; Mainul Haque; Marquita Gittens-St Hilaire
Journal:  Infect Drug Resist       Date:  2020-12-29       Impact factor: 4.003

Review 10.  Impact of formulary restriction with prior authorization by an antimicrobial stewardship program.

Authors:  Erica E Reed; Kurt B Stevenson; Jessica E West; Karri A Bauer; Debra A Goff
Journal:  Virulence       Date:  2012-11-15       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.